Expertise in
4
conditions

Dr. Sarah A. Cooley

Hematology | Oncology
Fairview Pharmacy Services LLC
516 Delaware St SE, 
Minneapolis, MN 
24 Years of Experience
Expertise in
4
conditions
Fairview Pharmacy Services LLC
516 Delaware St SE, 
Minneapolis, MN 

Overview

Sarah Cooley is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota. She has been practicing medicine for over 24 years.

Dr. Cooley is highly rated in 4 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 111 peer reviewed articles and participating in 7 clinical trials.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in MN

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

HealthPartners
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Fairview Pharmacy Services LLC
516 Delaware St SE, Minneapolis, MN 55455

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

QUILT-3.033: Haploidentical Donor Natural Killer (NK) Cell Infusion With Subcutaneous ALT-803 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia
QUILT-3.033: Haploidentical Donor Natural Killer (NK) Cell Infusion With Subcutaneous ALT-803 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia
Enrollment Status: Completed
Publish Date: July 18, 2023
Intervention Type: Biological
Study Phase: Phase 2
GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis
GTB-3550 (CD16/IL-15/CD33)Tri-Specific Killer Engager (TriKE®) for the Treatment of High Risk Myelodysplastic Syndromes, Refractory/Relapsed Acute Myeloid Leukemia and Advanced Systemic Mastocytosis
Enrollment Status: Terminated
Publish Date: November 10, 2022
Intervention Type: Drug
Study Drug: GTB-3550 TriKE CD33-Positive Myeloid-Derived Suppressor Cells
Study Phase: Phase 1/Phase 2
Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) With Subcutaneous IL-2 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) With Subcutaneous IL-2 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)
Enrollment Status: Completed
Publish Date: March 12, 2021
Intervention Type: Biological
Study Phase: Phase 1
A Randomized Trial Comparing CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for Adults With Acute Myelogenous Leukemia Who Have Failed 1 or 2 Induction Attempts
A Randomized Trial Comparing CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for Adults With Acute Myelogenous Leukemia Who Have Failed 1 or 2 Induction Attempts
Enrollment Status: Terminated
Publish Date: July 09, 2020
Intervention Type: Device
Study Phase: Not Applicable
Multi-Center Phase II Trial of NK Cell Based Non-Myeloablative Haploidentical Transplantation for Patients With High-Risk Acute Myeloid Diseases
Multi-Center Phase II Trial of NK Cell Based Non-Myeloablative Haploidentical Transplantation for Patients With High-Risk Acute Myeloid Diseases
Enrollment Status: Completed
Publish Date: May 13, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients With High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Enrollment Status: Unknown
Publish Date: June 29, 2017
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

111 Total Publications

Longitudinal Changes in Cognition and Brain Imaging in Persons With Human Immunodeficiency Virus.
Longitudinal Changes in Cognition and Brain Imaging in Persons With Human Immunodeficiency Virus.
Journal: The Journal of infectious diseases
Published: October 09, 2025
Similar Doctors
Expertise in
9
conditions
Dr. Mukta Arora
Hematology | Oncology
Expertise in
9
conditions
Dr. Mukta Arora
Hematology | Oncology
Referral may be required

Fairview Pharmacy Services LLC

516 Delaware St SE, 
Minneapolis, MN 
 (0.1 miles away)
612-273-2800
Languages Spoken:
English
See accepted insurances

Mukta Arora is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Arora is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), Graft Versus Host Disease (GvHD), Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
13
conditions
Dr. Yoav H. Messinger
Hematology | Oncology
Expertise in
13
conditions
Dr. Yoav H. Messinger
Hematology | Oncology
Referral may be required

Childrens Home Care Pharmacy

2530 Chicago Ave, 
Minneapolis, MN 
 (1.9 miles away)
612-813-5940
Languages Spoken:
English, Hebrew
See accepted insurances
Accepting New Patients

Yoav Messinger is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Messinger is highly rated in 13 conditions, according to our data. His clinical expertise encompasses DICER1 Syndrome, Sertoli-Leydig Cell Tumor, Pleuropulmonary Blastoma, Leydig Cell Testicular Tumor, and Bone Marrow Transplant. Dr. Messinger is currently accepting new patients.

Expertise in
10
conditions
Dr. Christopher L. Moertel
Hematology | Oncology
Expertise in
10
conditions
Dr. Christopher L. Moertel
Hematology | Oncology
Referral may be required

University Of Minnesota Medical Center Fairview Riverside

2450 Riverside Ave, 
Minneapolis, MN 
 (0.5 miles away)
612-365-8100
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Christopher Moertel is a Hematologist and an Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Moertel is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Malignant Peripheral Nerve Sheath Tumor, and RASopathies. Dr. Moertel is currently accepting new patients.

Frequently Asked Questions about Dr. Sarah A. Cooley

How do I make an appointment with Dr. Sarah A. Cooley?

You can book an appointment with Dr. Sarah A. Cooley by calling their office at 612-626-2663. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Sarah A. Cooley a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Sarah A. Cooley is classified as an Distinguished expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Sarah A. Cooley specialize in?

While Dr. Sarah A. Cooley is a Hematology, they have specific expertise in Acute Myeloid Leukemia (AML), Leukemia, and Acute Myeloblastic Leukemia without Maturation. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Sarah A. Cooley participate in research or clinical trials?

Yes. Dr. Sarah A. Cooley has published 111 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Sarah A. Cooley's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Sarah A. Cooley accept my insurance?

Dr. Sarah A. Cooley accepts most major insurance plans, including HealthPartners and Medica. We recommend calling the office directly at 612-626-2663 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cooley's expertise for a condition
ConditionClose
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile